Inflammatory%20bowel%20disease News

News

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

Jairia Dela Cruz, 20230522140000

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

Stephen Padilla, 20230522120000

Use of ustekinumab for up to 4 years in paediatric patients with Crohn’s disease (CD) shows similar efficacy, safety, pharmacokinetics (PK), and immunogenicity to that seen in adult patients, according to the results of the UniStar study long-term extension.

Herbal combination works in treatment of active ulcerative colitis

20230520180000

The herbal combination of curcumin plus QingDai (CurQD) appears beneficial to patients with active ulcerative colitis (UC), with a recent study showing that the combination induced clinical and biomarker remission.

Broad-spectrum antibiotic exposure ups risk of IBD

20230520060000

Exposure to broad-spectrum antibiotics may put individuals at risk of developing inflammatory bowel disease (IBD), such that the greater the dose, the higher the risk, as shown in a study.

Older IBD patients at disadvantage for medications, surgery

20230429180000

Older patients with inflammatory bowel disease (IBD) are less likely to be initiated on medications and are often scheduled for surgeries, a study has found.

IBD patients at higher risk of Alzheimer’s disease

20230413130000

Inflammatory bowel disease (IBD) shows an independent relationship with the development of Alzheimer’s disease (AD), with such association being stronger in patients with Crohn’s disease (CD) than those with ulcerative colitis (UC), reveals a study.

Maternal Crohn’s disease ups risk of infection in offspring

20230326110000

Offspring born to mothers with Crohn’s disease (CD), but not ulcerative colitis, are at higher risk of infection, suggests a study. This association is partly mediated by adverse birth outcomes and antitumour necrosis factor α (anti-TNFα) agents.

5-ASA maintenance therapy of little help in patients with newly diagnosed CD

20230323060000

Maintenance treatment with 5-aminosalicylates (5-ASA) in patients with newly diagnosed Crohn's disease (CD) does not appear to lead to better outcomes as compared with a watchful waiting approach, according to a study.

Real-world use affirms benefits of upadacitinib for inflammatory bowel disease

20230314180000

The use of the novel selective JAK-1 inhibitor upadacitinib appears to result in rapid symptom improvements in patients with difficult-to-treat ulcerative colitis or Crohn’s disease, including those who have prior exposure to tofacitinib, according to real-world data.

FMT prevents recurrent C. difficile infection in IBD patients

20230223110000

Patients with inflammatory bowel disease (IBD) who undergo foecal microbiota transplantation (FMT) are less likely to develop recurrent Clostridioides difficile infection (CDI), a study has shown.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules